Pain News and Research

Latest Pain News and Research

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it has entered into a termination agreement with AstraZeneca, such that all the rights to Ardelyx's portfolio of NHE3 inhibitors, including Ardelyx's lead product candidate, tenapanor, are returned to Ardelyx.

3 Jun 2015

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.

3 Jun 2015

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Prostate cancer is the second most common cancer and the second leading cause of cancer-related deaths among men in the U.S...

3 Jun 2015

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel.

3 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Northeastern University researchers report two approaches to eradicate Lyme disease

Northeastern University researchers have found that the bacterium that causes Lyme disease forms dormant persister cells, which are known to evade antibiotics. This significant finding, they said, could help explain why it's so difficult to treat the infection in some patients.

2 Jun 2015

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data.

2 Jun 2015

Study addresses children's basic perspectives on living with Type 1 diabetes

If a picture is worth a thousand words, UF Health Type 1 diabetes researchers and their colleagues have tapped into an encyclopedia, revealing new insights into how young people cope with the disease.

2 Jun 2015

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology Annual Meeting, May 29-June 2, Chicago, Illinois.

2 Jun 2015

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

2 Jun 2015

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Upsher-Smith Laboratories, Inc. announced that it has received U.S. Food and Drug Administration approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures.

2 Jun 2015

Zinc levels linked to formation of kidney stone

New research on kidney stone formation reveals that zinc levels may contribute to kidney stone formation, a common urinary condition that can cause excruciating pain. The research found that zinc may be the core by which stone formation starts.

2 Jun 2015

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Researchers from the University of Liverpool have found that approximately half of patients who have an eye removed because of a form of eye cancer experience 'phantom eye syndrome.'

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.

2 Jun 2015

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the North American Spine Society (NASS) has issued their formal coverage recommendation for MIS SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion, Defining Appropriate Coverage Positions."

1 Jun 2015

BioDelivery Sciences secures additional $20.7M in gross debt funding from MidCap Financial

BioDelivery Sciences International, Inc. announced today that it has secured an additional $20.7 million in gross debt funding from MidCap Financial to bring BDSI's total outstanding debt with MidCap to $30 million in a single senior secured loan.

1 Jun 2015

ACA urges NINDS to include recommendations for use of conservative forms of pain management

The American Chiropractic Association (ACA), in recent comments submitted to the National Institute of Neurological Disorders and Stroke (NINDS) Office of Pain Policy on the draft National Pain Strategy, strongly urges the agency to include recommendations encouraging patients and health care providers to first exhaust conservative forms of pain management, when appropriate.

1 Jun 2015

Pain News and Research

Latest Pain News and Research

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Women who suffer from fibromyalgia benefit from hyperbaric oxygen therapy

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Northeastern University researchers report two approaches to eradicate Lyme disease

Substantial pharmacogenetic information available on cardiovascular drugs

Study addresses children's basic perspectives on living with Type 1 diabetes

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Upsher-Smith announces FDA approval of sNDA for Qudexy XR extended-release capsules

Zinc levels linked to formation of kidney stone

More patients experience phantom eye symptoms every day, say University of Liverpool researchers

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

BioDelivery Sciences secures additional $20.7M in gross debt funding from MidCap Financial

ACA urges NINDS to include recommendations for use of conservative forms of pain management

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Pain News and Research

Latest Pain News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in